You have 9 free searches left this month | for more free features.
Clincosm LogoSign in Get a demo

Neurofibromatosis

Showing 1 - 25 of 260
STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS
LAST UPDATED

Mitochondrial Dysfunction in Neurofibromatosis Type 1

Not yet recruiting
  • Neurofibromatosis 1
  • Blood draw
  • FACIT-F and Pain Scales
  • (no location specified)
Jun 12, 2023

Neurofibromatosis 1 Trial in Boston (Kybella, Asclera)

Recruiting
  • Neurofibromatosis 1
  • Boston, Massachusetts
    Wellman Center for Photomedicine
Nov 1, 2023

Neurofibromatosis 1 Trial in Boston (Deoxycholic Acid, Polidocanol, 1064nm Nd:YAG laser)

Not yet recruiting
  • Neurofibromatosis 1
  • Deoxycholic Acid
  • +3 more
  • Boston, Massachusetts
    Wellman Center for Photomedicine
Nov 13, 2023

Natural History Study of Patients With Neurofibromatosis Type 2

Recruiting
  • Neurofibromatosis
    • Bethesda, Maryland
      National Institutes of Health Clinical Center
    Jan 25, 2023

    Neurofibromatosis 1, Plexiform Neurofibroma, NF1 Trial (Test group (Group A): FCN-159 8 mg, orally, once daily;, Control group

    Not yet recruiting
    • Neurofibromatosis 1
    • +2 more
    • Test group (Group A): FCN-159 8 mg, orally, once daily;
    • Control group (Group B): Placebo, orally, once daily;
    • (no location specified)
    Jun 16, 2023

    Biology of Skin Neurofibromas in Neurofibromatosis Type 1

    Completed
    • Neurofibromatosis Type 1
    • Neurofibroma
      • Bethesda, Maryland
        National Institutes of Health Clinical Center
      Jan 20, 2023

      US Selumetinib Registry

      Not yet recruiting
      • Neurofibromatosis Type 1
      • Plexiform Neurofibromas
        • (no location specified)
        Jan 5, 2023

        Neurofibromatosis 1, Neurofibroma, Plexiform Trial run by the NCI (Medication Event Monitoring System (MEMS))

        Active, not recruiting
        • Neurofibromatosis 1
        • Neurofibroma, Plexiform
        • Medication Event Monitoring System (MEMS)
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Feb 2, 2023

        Neurofibromatosis 1 Trial run by the National Cancer Institute (NCI) (Abemaciclib)

        Recruiting
        • Neurofibromatosis 1
        • Bethesda, Maryland
          National Institutes of Health Clinical Center
        Jan 20, 2023

        (PRO) Measures for Individuals With Neurofibromatosis 1 and

        Recruiting
        • Neurofibromatosis 1
        • Plexiform Neurofibromas
          • Bethesda, Maryland
            National Institutes of Health Clinical Center
          Feb 2, 2023

          Development to Predict Malignant Conversion in Neurofibromatosis

          Recruiting
          • Neurofibromatosis 1
          • +2 more
          • Whole Body Magnetic Resonance Imaging
          • Baltimore, Maryland
            Johns Hopkins University
          Dec 22, 2022

          Disfigurement From Photographs of Neurofibromatosis Type 1

          Completed
          • Neurofibromatosis 1
            • Bethesda, Maryland
              National Institutes of Health Clinical Center
            Jan 20, 2023

            Neurofibromatosis 1, Neurofibroma Plexiform Trial in Shanghai (Selumetinib)

            Active, not recruiting
            • Neurofibromatosis 1
            • Neurofibroma Plexiform
            • Shanghai, China
            • +1 more
            Jan 13, 2023

            Neurofibromatosis 1 (NF1), Plexiform Neurofibromas (PN) Trial run by the NCI (Selumetinib)

            Active, not recruiting
            • Neurofibromatosis 1 (NF1)
            • Plexiform Neurofibromas (PN)
            • Bethesda, Maryland
              National Institutes of Health Clinical Center
            Jan 31, 2023

            Cutaneous Neurofibromas in People With NF1

            Recruiting
            • Neurofibromatosis Type 1
            • +3 more
            • Evaluation of the natural history of cutaneous neurofibromas
            • Baltimore, Maryland
              Johns Hopkins University
            Oct 12, 2022

            Stressors in Parents of Cancer or Neurofibromatosis Type 1 (NF1)

            Completed
            • Parents of Children With Cancer
            • +2 more
              • Bethesda, Maryland
                National Institutes of Health Clinical Center
              Jan 26, 2023

              Neurofibromatosis 1 Trial in Baltimore, Redwood City

              Recruiting
              • Neurofibromatosis 1
                • Baltimore, California
                • +1 more
                Aug 17, 2022

                89Zr-Bevacizumab PET/CT Imaging in NF2 Patients

                Recruiting
                • Neurofibromatosis 2
                • Bevacizumab Zirconium Zr-89
                • Leiden, Zuid-Holland, Netherlands
                  Leiden University Medical Center
                Jan 5, 2023

                Neurofibromatosis, MPNST Trial run by the National Cancer Institute (NCI) (MRI, FDG-PET/CT scans, [18F]-FLT-PET/CT scans)

                Completed
                • Neurofibromatosis
                • MPNST
                • MRI, FDG-PET/CT scans
                • [18F]-FLT-PET/CT scans
                • Bethesda, Maryland
                  National Institutes of Health Clinical Center, 9000 Rockville Pi
                Aug 24, 2022

                Cutaneous Neurofibroma Trial in Boston (Kybella, 980nm laser, 755nm Alexandrite Laser)

                Recruiting
                • Cutaneous Neurofibroma
                • Boston, Massachusetts
                  Wellman Center for Photomedicine, Massachusetts General Hospital
                Aug 10, 2022

                Neurofibromatosis Type 1 Trial in Los Angeles (Whole-body Magnetic Resonance Imaging)

                Recruiting
                • Neurofibromatosis Type 1
                • Whole-body Magnetic Resonance Imaging
                • Los Angeles, California
                  Cedars Sinai Medical Center
                Jul 11, 2022

                Neurofibromatosis Type 1, Plexiform Neurofibromas, Post-operative Trial in Beijing, Shanghai (Selumetinib, Placebo)

                Not yet recruiting
                • Neurofibromatosis Type 1
                • +2 more
                • Beijing, China
                • +2 more
                Apr 11, 2023

                PASS of Paediatric Patients Initiating Selumetinib

                Recruiting
                • Neurofibromatosis Type 1
                  • Angers, France
                  • +3 more
                  Jan 12, 2023

                  Frameshift Peptides of Children With NF1

                  Completed
                  • Neurofibromatosis Type 1
                  • Frameshift Array blood sample test
                  • Washington, District of Columbia
                  • +2 more
                  Aug 29, 2022

                  Neurofibromatosis Type 1 Trial in Worldwide (Selumetinib)

                  Active, not recruiting
                  • Neurofibromatosis Type 1
                  • Rochester, Minnesota
                  • +8 more
                  Nov 10, 2022